Objective. To provide the pediatric intensivist an in-depth understanding of citrate as regional anticoagulant during continuous renal replacement therapy. Data Sources and Data Selection.

Anticoagulation for 5 to 11 days after hip ... for the prevention of DVT after orthopedic surgery and does not require therapeutic monitoring. In a manufacturer-funded, double-blind ...

During a Case-Based Roundtable® event, Joshua K. Sabari, MD, continued discussion of key outcomes from the MARIPOSA trial and ...

Acute coronary syndrome (ACS) is a term used to describe a range of conditions resulting from the sudden reduction or ...

Submission of a Prior Approval Supplement for a reduction in the number of patients in the NEPHRO CRRT study is expected within ...

Talphera (TLPH) announced that following a meeting with the FDA, the agency has agreed to review a Prior Approval Supplement requesting a ...

( MENAFN - JCN NewsWire) FDA Accepts LEQEMBI (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the treatment of Early Alzheimer's disease LEQEMBI is the only ...

AstraZeneca's anticoagulant reversal agent Andexxa was ... so keeping the only approved therapy on the market makes sense, even if the FDA asks for additional data. Join the conversation, on ...

The ARIES-HM3 substudy may help persuade implanters who are less well-versed in the circulatory changes an LVAD affords.

Boston Scientific outperforms competitors with strong growth in atrial fibrillation devices and recent acquisitions. Learn ...

Benefiting from technological and conceptual groundwork and positive early data, gene therapies are advancing in the clinic ...

Dupixent® is now used to treat over a million patients globally, with continued growth and expansion in multiple indications for diseases in ...